Medical Writing for Regulatory Strategy & Submissions

Navigate development milestones with scientifically rigorous, strategically aligned regulatory documentation. 

Schedule a Call

When to use this service

You're a biotech, startup, or pharma company planning regulatory pathways and need expert-led medical writing to:

  • Prepare for scientific advice meetings (EMA, FDA)
  • Build CTD clinical modules and regulatory packages
  • Respond to authority questions with strength
  • Support investment due diligence with clear, cohesive development narratives
  • Coordinate cross-functional documentation (clinical, CMC, non-clinical, statistics) for submissions
hVIVO Drug Development Consultants

What We Deliver

Scientific advice briefing packages and meeting requests

Common Technical Document (CTD) clinical modules for IND, CTA, NDA/MAA submissions

Integrated responses to authority questions

Development strategy briefs for investors and boards

DSUR (Development Safety Update Reports) and other post-authorisation documents

Clinical study reports with CMC and statistical context

Lay summaries for public submissions

Regulatory narratives that connect trial data to development strategy

Integrated safety and efficacy summaries for submissions

Our Process

Regulatory pathway assessment and planning

We start by understanding your programme maturity, target indication, and regulatory strategy. This shapes everything; document scope, content priorities, review timelines. A first-in-human programme needs different briefing books than a phase III to NDA transition.

Cross-functional input coordination (clinical, CMC, non-clinical, biostatistics)

We pull together clinical data, CMC manufacturing facts, non-clinical safety findings, and biostatistical analysis from your team and external specialists. Rather than writers working in isolation, we coordinate these inputs upfront so documents are built on solid, agreed-upon foundations. This catches misalignments early. 

Document strategy and structure alignment

Before drafting, we map out how documents connect, how your CTD narrative flows from scientific advice responses through IND preparation, how CMC and clinical modules coordinate, how a lay summary captures the true development story. This prevents fragmented submissions that feel like separate documents glued together.
Learn more

Collaborative authoring

Lead writers work closely with your team, consultants, and SMEs. You see drafts early, provide input, and we iterate. This keeps documents aligned with your thinking and catches strategic gaps before final QC. 

Authority-ready QC and format preparation

Final documents go through formal quality control including regulatory compliance, formatting consistency, data traceability, compliance with guidance. Documents arrive ready to submit. 

Why This Matters

Most regulatory submissions fail not because the data is weak, but because reviewers can't follow the development story. A scientific advice briefing that doesn't anticipate authority concerns wastes the meeting. A CTD that contradicts itself across modules raises red flags. A response to an authority question that doesn't connect to your broader strategy looks defensive.

By coordinating clinical, CMC, and statistical writing from the start, we ensure every document reinforces the same narrative. Your reviewers see a coherent development programme, not scattered documents. That alignment directly impacts how authorities perceive risk and probability of success.

For Startups & Biotechs

Early stage programmes need regulatory clarity fast. We provide:

  • Targeted scientific advice preparation to de-risk development decisions
  • First-submission support for IND/CTA packages
  • Flexible engagement (project-based or programme advisory)
  • Access to consultants who've navigated the same pathway with other programmes

For Pharma & CROs

Complex programmes need consistency and speed. We provide:

  • Dedicated lead writers for multi-year programmes
  • Template management and cross-document consistency checks
  • Authority response turnaround that meets aggressive timelines
  • Integration with your existing teams and sponsor SOPs

FAQ

We provide comprehensive medical writing support across the full clinical development pathway. This includes trial outlines, protocols and amendments, investigator’s brochures (IBs), participant information leaflet – informed consent forms (PIS-ICFs), clinical study reports (CSRs), narratives, lay summaries, abbreviated CSRs, and scientific publication of trial results., Scientific advice briefing packages, CTD clinical modules and other regulatory documents can be developed for you for regulatory agency interactions .

Our writing approach is grounded in scientific excellence and regulatory alignment. We use guidance‑aligned templates, standardised terminology, clear data traceability, and a multi‑layer QC process to ensure accuracy. Cross‑document consistency checks maintain alignment across protocols, PIS-ICFs, IBs, and CSRs, but also across CSRs and briefing packages or CTDs. Every document is reviewed through a structured QA process to ensure it meets regulatory expectations.

We use a structured review framework that  streamlines collaboration across the team and with the sponsor. This includes clear review timelines, consolidated review comment logs, tracked adjudication of relevant comments, proactive clarification with SMEs before revisions are made, and comment resolution meetings, when required. Strong version control and decision‑tracking ensure documents move through each iteration smoothly and efficiently.

 

 

Yes. We prepare full scientific advice packages, including meeting requests, briefing books, and written responses to authority questions.

Yes. We structure projects with clear dependencies and parallel workstreams. Lead writers and dedicated QC teams protect timelines even under pressure. 

We adapt to sponsor SOPs, regulatory frameworks, and templates. If you have established processes, we follow them. If you need process setup, we can help.

Early phase through late stage. We've supported scientific advice for first-in-human studies, CMC submissions for phase transitions, and full CTD preparation for NDA/MAA filings. 
Full integrated regulatory packages. We coordinate with specialists in CMC, biostatistics, and non-clinical disciplines to ensure consistency and regulatory alignment across all CTD modules. 
Yes. We create regulatory development narratives and briefing materials that help investors understand programme risk, competitive positioning, and pathway probability. 

Contact Us